| Use of nifedipine during cardiac surgery for improved myocardial protection. | |
| | |
MedLine Citation:
|
PMID: 3883767 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The combined results of extended clinical trials conducted in two centers following successful laboratory trials are evaluated. From a population of 4,777 patients who underwent open heart surgery, 205 high-risk patients were selected for study. One hundred seventy patients (3.6 percent) were given nifedipine in cardioplegic solution. The remaining 35 patients served as control subjects and were compared with 39 treated patients in the randomized subset of 74. One third of the patients underwent valve replacement, one quarter underwent coronary artery bypass, and 40 percent underwent combinations of valve replacement, coronary artery bypass, and other procedures. Characteristically, the third group had a 50 percent increase in end-diastolic volumes and low cardiac indexes (1.7 +/- 0.1 liters/minute/m2). Average cross-clamp time was 77 minutes. At one center, an extracellular hyperkalemic-type solution was used to deliver an average dose of 407 +/- 22 micrograms nifedipine per patient. At the other center, a low-sodium hyperkalemic solution was used, and the average nifedipine dose was 476 +/- 22 micrograms. Hemodynamic studies in the randomized subset demonstrated approximately a twofold improvement in the treated group in cardiac index, stroke volume, stroke work index, and pulmonary vascular resistance following cardiopulmonary bypass. The incidence of acute low cardiac output death was 4 percent versus 11 percent in the control group. Survival for all treated patients was 86 percent. It is concluded that the addition of nifedipine reduced the incidence of acute global cardiac failure in the immediate postoperative interval. |
| | |
Authors:
|
R E Clark; I Y Christlieb; G J Magovern |
Related Documents
:
|
20206847 - Nitric oxide index is not a predictor of cognitive dysfunction following laparotomy. 22414987 - Cost-effectiveness analysis of infrapopliteal drug-eluting stents. 20823387 - Scimitar syndrome: a european congenital heart surgeons association (echsa) multicentri... 23314877 - Acute adrenal failure following anticoagulation with dabigatran after hip replacement a... 21322467 - Idiopathic itch, rash, and urticaria/angioedema merit serum vitamin d evaluation: a des... 18025627 - Site of incision and corneal astigmatism in conventional sics versus phacoemulsification. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: The American journal of medicine Volume: 78 ISSN: 0002-9343 ISO Abbreviation: Am. J. Med. Publication Date: 1985 Feb |
Date Detail:
|
Created Date: 1985-03-26 Completed Date: 1985-03-26 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0267200 Medline TA: Am J Med Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 6-8 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cardiac Output
/
drug effects Cardiac Surgical Procedures* Clinical Trials as Topic Heart Diseases / prevention & control* Humans Intraoperative Period Nifedipine / therapeutic use* Postoperative Complications / prevention & control Pulmonary Circulation / drug effects Stroke Volume / drug effects Vascular Resistance / drug effects |
| Grant Support | |
ID/Acronym/Agency:
|
R01 HL17646/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
21829-25-4/Nifedipine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Therapeutic drug-use review for the Florida Medicaid program.
Next Document: Calcium metabolism and parathyroid function in primary aldosteronism.